The present invention relates a new process to synthesize 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine (AL3818). A stable crystalline form of A13818 has been prepared. Salts and their crystalline forms of AL3818 have been also prepared. Anti-cancer and optometric activities of AL3818 and its salts have been further tested. New process has been outlined in Scheme I.

##STR00001##

The present invention relates a new process to synthesize 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine (AL3818). A stable crystalline form of A13818 has been prepared. Salts and their crystalline forms of AL3818 have been also prepared. Anti-cancer and optometric activities of AL3818 and its salts have been further tested. New process has been outlined in Scheme I.

##STR00001##

The disclosure provides a water soluble pouch including at least two sealed compartments, the pouch including outer walls including water soluble film including a water soluble resin, and an inner wall including water soluble film including a water soluble resin, the outer wall films being sealed to the inner wall film, the outer wall films being characterized by: a dissolution time of 300 seconds or less, the water soluble resin of the outer wall films having a viscosity in a range of 14.5 cP to 25cP, and a pouch strength of at least 200 N, and the inner wall film being characterized by: a dissolution time of 300 seconds or less, the water soluble resin of the inner film having viscosity in a range of 12 cP to 14.5 cP, and a tackiness value of at least 1500 g/s.

The disclosure provides a water soluble pouch including at least two sealed compartments, the pouch including outer walls including water soluble film including a water soluble resin, and an inner wall including water soluble film including a water soluble resin, the outer wall films being sealed to the inner wall film, the outer wall films being characterized by: a dissolution time of 300 seconds or less, the water soluble resin of the outer wall films having a viscosity in a range of 14.5 cP to 25cP, and a pouch strength of at least 200 N, and the inner wall film being characterized by: a dissolution time of 300 seconds or less, the water soluble resin of the inner film having viscosity in a range of 12 cP to 14.5 cP, and a tackiness value of at least 1500 g/s.

The present invention relates to the use of a first water-soluble film and a second water-soluble film to make a unit dose article and the use of said unit dose article.

The present invention relates to the use of a first water-soluble film and a second water-soluble film to make a unit dose article and the use of said unit dose article.

The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.

The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.

The present application relates to a salt formed from a compound of formula (I) with an acid:

##STR00001## wherein the acid is selected from hydrochloric acid, methanesulfonic acid, benzenesulfonic acid, ethanesulfonic acid, maleic acid, hydrobromic acid, citric acid, L-tartaric acid, and p-toluenesulfonic acid. The present application also relates to a method for treating non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation using the salt.

The present disclosure relates generally to various forms and compositions useful as beta adrenergic agonists and uses of the same in the treatment of diseases associated with an adrenergic receptor. In one aspect, the disclosure provides a crystalline solid form of Compound 1: selected from Form A and Form B and salt forms thereof.

##STR00001##